Certara
@Certara
Followers
2K
Following
736
Media
5K
Statuses
7K
Accelerating medicines to patients with biosimulation, technology and services.
Radnor, PA (Headquarters)
Joined November 2011
PBPK Consultant 1–3 yrs PBPK, PhD https://t.co/AIDdshnsLf Senior PBPK Consultant (Italy) 4–5 yrs PBPK, PhD https://t.co/wyCWRxqeL5 Principal PBPK Consultant 6–7 yrs PBPK, PhD https://t.co/k416VQG0kt Senior Director, PBPK Consultancy 10–15 yrs PBPK, PhD https://t.co/kgTwv5fFTR
0
0
0
Excited to share that Piet van der Graaf, Certara’s Head of QSP, will speak at the PopSim QSP Symposium on 26 Nov 2025 (13:35–14:20) at Ferring Pharma. His talk: “QSP has come of age—implementing at scale across discovery, development & regulatory.” #QSP #Pharmacometrics #PopSim
0
0
1
Join Certara and Fierce Biotech for this insightful webinar. Failure to Launch – Building Smarter Strategies to Get the Right Drug to the Right Patient | Dec 16 | 11 AM ET Register now: https://t.co/JYrxhx2a0m
#Biotech #DrugDevelopment #Innovation
0
0
1
𝗝𝗼𝗶𝗻 𝗨𝘀 𝗮𝘁 𝗥𝗘𝗦𝗜 𝗟𝗼𝗻𝗱𝗼𝗻 𝟮𝟬𝟮𝟱! Stop by our booth to see how Certara helps startups de-risk programs, strengthen due diligence, and turn novel science into investable opportunities. Let’s connect in London! https://t.co/hKlrgdMy3W
#RESILondon #LifeScience
0
0
0
𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆: Certara helped Ionis accelerate FDA submission for Donidalorsen (HAE therapy) using biomarker + exposure–response modeling to support less frequent dosing. 🔗 https://t.co/ktXw1aeGew
#HAE #RareDisease #MIDD #Pharmacometrics
0
0
0
Can you predict human PK from animal data? Learn how on Dec 10 @ 11 a.m. ET Join our webinar to learn how time-invariant methods improve translational accuracy across species. Register: https://t.co/1kxZm9fNdl
#Pharmacokinetics #PKModeling
0
0
0
Join Certara and Fierce Biotech for this insightful webinar. Failure to Launch – Building Smarter Strategies to Get the Right Drug to the Right Patient | Dec 16 | 11 AM ET Register now: https://t.co/rkXXtnuD1w
#Biotech #DrugDevelopment #Innovation
0
0
1
ADCs are transforming oncology—yet their PK is complex. Learn how PopPK modeling brings clarity to ADC programs in our on-demand webinar with Certara + Avidity. Watch now: https://t.co/onzoejO7j8
#ADC #PopPK
0
0
1
Stop waiting for clinical trials to learn if your drug will succeed. EFA powered by QSP helps you predict dosing, assess druggability & reduce early-stage risk. 📘 Get the free guide: https://t.co/pmLtkzR7QD
#EFA #QSP
0
0
2
PHUSE EU kicks off in Hamburg! Join our experts on Nov 19 for three can’t-miss sessions covering RWD insights, SDTM/ADaM conversion, and SDTM best practices for ongoing studies. Full schedule: https://t.co/RRW1bAd7et
#PHUSE #CDISC #ClinicalTrials #Pinnacle21
0
0
1
Certara partnered with KalVista to accelerate NDA submission for a novel HAE therapy—delivering PK/PD, ER, and pediatric dose modeling for FDA and EMA review. Read more: https://t.co/yWmetMCJCA
#HAE #RareDisease #MIDD #Pharmacometrics
0
0
2
Alzheimer’s trials are complex. 🧠 Dr. Rajesh Krishna shows how exposure-response, biomarkers & disease modeling can guide earlier, evidence-based decisions. Read more: https://t.co/50Pl6hxJlg
#AlzheimersDisease #MIDD
0
0
1
Join us at #ACT2025! Certara’s Joshuaine Grant presents how QSP modeling improves preclinical efficiency while reducing animal use. 📍 Poster P121 | Nov 17 | 5–6:30 PM Learn more: https://t.co/aHZaVRf57s
#QSP #MIDD #NAMs #DrugDevelopment
0
0
2
Join us Mar 2–3, 2026 in D.C. for the Simcyp PBPK Biopharmaceutics Workshop! Hands-on sessions on formulation, virtual bioequivalence & safe space assessment. Connect with experts & level up your PBPK skills. https://t.co/gZDk3biNPW
#PBPK #DrugDevelopment #Biopharmaceutics
0
0
1
Meet Certara IQ™ — AI-powered QSP modeling that turns months of work into days. 🚀 Watch our on-demand webinar to see how it accelerates decisions, automates workflows, and scales QSP across pipelines. 🔗 https://t.co/TIAFWWvoAq
#CertaraIQ #QSP #MIDD #AIinDrugDiscovery
0
0
1
Most drugs fail because feasibility questions come too late. See how Early Feasibility Assessment (EFA) with QSP modeling predicts success before trials. 📘 Free guide: https://t.co/m0vH2WrbtN
#EFA #QSP #DrugDevelopment
0
0
2
~80% predictive accuracy for ADA impact! Our new Frontiers in Immunology paper shows how the [ADA]:[Drug] ratio predicts when anti-drug antibodies affect exposure—advancing early de-risking in biologics. 🔗 https://t.co/CdsiaqKgQO
#CertaraIQ #Immunogenicity #Biologics #QSP
0
0
0
Join us in Washington, D.C., on March 2–4, 2026, for the Simcyp Focus Group Workshop on PBPK Modeling Best Practices! Gain hands-on experience, explore case studies, and learn how PBPK modeling drives smarter drug development. 🔗 Register here: https://t.co/3lsDRGiEh9
0
0
1
Don’t miss the CHI webinar on Navigating Regulatory Submissions with Pharmacometrics! Join Certara’s Dr. Felix Boakye-Agyema and Huub Jan Kleijn for insights to accelerate timelines and streamline interactions. https://t.co/eKSulMGScn
0
0
1
How do you pick the right dose without validated biomarkers or head-to-head data? A new CPT paper shows how model-informed methods guided milvexian dose selection in AFib. 🔗 https://t.co/MwW7ULY9KW
#MIDD #DrugDevelopment
0
0
2